This archive covers progress stories and milestones from across Europe, spanning health, climate policy, social equity, and scientific research. From small-nation experiments to E.U.-wide initiatives, these reports highlight what is working and why.
Rich nations, which bear the brunt of responsibility for warming the atmosphere, have long resisted making such payments, seeking to avoid assuming legal liability for their contributions to climate change.
Lab-grown blood cells have reached a genuine turning point: manufactured red blood cells grown from stem cells have been safely transfused into human patients for the first time. What makes these cells special is their freshness — unlike donated blood, every lab-grown cell is the same age, meaning they should last closer to the full 120-day lifespan and reduce repeat transfusions. Early participants completed the process with no adverse effects. For millions worldwide living with blood disorders or rare blood types, this science crossing into human trials is the kind of progress that quietly changes everything.
This decision puts Icelandair at the forefront of sustainable aviation, considering that many other airlines are only aiming to reach net-zero emissions by 2050.
In the deal, the Nordic country will pay Indonesia, home to the world’s third-largest tropical forests, to keep its forests standing, thereby reducing its emissions.
The Irish Cabinet has approved a bill that says anyone who is convicted of purposefully inciting hatred or violence against a person due to their gender identity or expression could face up to five years in prison.
Recreational cannabis legalization in Germany would mark a significant shift for Europe’s largest economy — moving the country away from a prohibition model that its own health minister says has shown no clear results. The proposal would allow licensed shops and pharmacies to sell cannabis to adults, with age-based limits on potency designed to protect younger users. Because Germany sits at the heart of the E.U., its approach could reshape how other member states think about drug policy far more than smaller precedents have. This is what evidence-based reform looks like in practice.
Sunak’s rise to the top office is especially significant in a country that has sometimes struggled to grapple with the legacy of its colonialist past.
Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.
Germany’s new program will support Afghans suffering persecution at the hands of the Taliban, including women’s and human rights advocates and people who have persecuted because of their religion, gender, or sexual orientation.
Irish company OceanEnergy has signed on to a four-year project to test, validate and commercialize he OE35, billed as the world’s largest capacity floating wave energy device, off the coast of Orkney, Scotland.
